title: Regenerative pharmacology for the treatment of acute kidney injury: Skeletal muscle stem/progenitor cells for renal regeneration?
abstract: Regenerative pharmacology and advanced therapy medicinal products is a relatively new and challenging field in drug development. Acute kidney injury (AKI) is a common clinical condition in nephrology with increasing incidence and high mortality rate. During the last few decades, researchers have been eagerly trying to find novel therapeutic strategies for AKI treatment, including advanced pharmacological therapies using mesenchymal stem cells (MSCs). Several types of MSCs have been thoroughly investigated, including bone marrow, adipose derived and umbilical cord blood MSCs and shown promising results in kidney repair. Research has demonstrated, that MSCs exert their effect through reduction of apoptosis, increased production of growth factors, suppression of oxidative stress and inflammatory processes, promotion of renal tubular cell proliferation, as well as by migration and direct incorporation into the renal tissue. Skeletal muscle-derived stem/progenitor cells (MDSPCs) are mesenchymal stem cell lineage of multipotent cells, demonstrating long-term proliferation, high self-renewal capacities, and ability to enhance endogenous tissue repair. The capacity of MDSPCs to regenerate a variety of different tissues following acute injury or destructive tissue diseases have been demonstrated in preclinical and clinical studies. MDSPCs were also reported to promote endogenous tissue repair via paracrine pathway. Considering advantageous properties of MDSPCs, the administration of these cells might be considered as a potential strategy for the treatment of AKI. However, to date, the therapeutic effect of MDSPCs for renal regeneration has not been investigated. This review reflects the current development in AKI treatment using different types of MSCs and the pilot results of the experimental study in vivo using a novel type of stem cells - MDSPCs for the treatment of gentamicin-induced AKI.
authors.affiliation: Institute of Physiology and Pharmacology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania. Electronic address: egle.svitojute@lsmuni.lt.
authors.forename: Egle
authors.initials: E
authors.lastname: Pavyde
authors.affiliation: Institute of Physiology and Pharmacology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania. Electronic address: arvydas.usas@lsmuni.lt.
authors.forename: Arvydas
authors.initials: A
authors.lastname: Usas
authors.affiliation: Institute of Physiology and Pharmacology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania; Department of Nephrology, Medical Academy, Lithuanian University of Health Sciences, LT-50009 Kaunas, Lithuania. Electronic address: romaldasmaciulaitis@vvkt.lt.
authors.forename: Romaldas
authors.initials: R
authors.lastname: Maciulaitis
mesh_terms: D058186:Acute Kidney Injury / Q000503:physiopathology* / Q000628:therapy*; D000818:Animals; D006801:Humans; D007668:Kidney / Q000502:physiology*; D059630:Mesenchymal Stem Cells; D018482:Muscle, Skeletal / Q000502:physiology*; D012038:Regeneration / Q000502:physiology*; D032496:Satellite Cells, Skeletal Muscle / Q000502:physiology*; D013234:Stem Cells / Q000502:physiology*
keywords: Acute kidney injury; Mesenchymal stem cells; Muscle-derived stem progenitor cells; Regenerative pharmacology